---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-071960"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:02:59.861571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Axsome Therapeutics stockholders elect directors, ratify auditor, approve executive compensation at 2024 annual meeting

## Summary
- Re-elected Herriot Tabuteau (33.3M for, 0.5M withheld) and Mark Coleman (27.1M for, 6.7M withheld) as Class III directors.
- Ratified Deloitte & Touche as independent auditor for FY2024 with 39.1M for, 0.15M against.
- Advisory vote approved named executive officer compensation: 32.9M for, 0.87M against.
- Approximately 84% of eligible shares (39.9M of 47.5M) were represented at the meeting.

## SEC filing metadata
- accession: 0000950170-24-071960
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024071960/0000950170-24-071960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024071960/axsm-20240607.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-071960
- JSON: https://secwatch.observer/filing/0000950170-24-071960.json
- Plain text: https://secwatch.observer/filing/0000950170-24-071960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.